Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2010 09:00 ET | Source: GlobeImmune Inc.

Phase 2b Study Demonstrates GlobeImmune's GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who Previously Failed Therapy With Standard of Care

LOUISVILLE, CO--(Marketwire - October 30, 2010) - GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company's investigational...
October 28, 2010 08:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Expands GI-5005-02 Phase 2b Trial to Include Additional Treatment Naive IL28B T/T Subjects With Chronic Genotype 1 HCV

LOUISVILLE, CO--(Marketwire - October 28, 2010) - GlobeImmune Inc. today announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment...
October 01, 2010 09:05 ET | Source: GlobeImmune, Inc.

GlobeImmune Announces Late-Breaker Oral Presentation of GI-5005 Prior Non-Responder Data at AASLD 2010 Meeting

LOUISVILLE, CO--(Marketwire - October 1, 2010) - GlobeImmune Inc. today announced that an abstract related to GI-5005, its Phase 2 investigational hepatitis C virus (HCV) product candidate, has...
April 19, 2010 14:12 ET | Source: GlobeImmune

GlobeImmunes Hepatitis-C-Arzneimittelkandidat führt bei allen All IL-28 B-Genotypen am Ende der Behandlung zu einer höheren Ansprechrate, wobei die größte Wirkung bei den am schwersten zu behandelnden Fällen zu verzeichnen ist

LOUISVILLE, COLORADO--(Marketwire - April 19, 2010) - GlobeImmune Inc. gab Ergebnisse der Phase 2b mit GI-5005, dem in Entwicklung befindlichen Tarmogen(R)-Arzneimittel gegen Infektionen mit dem...
April 19, 2010 07:00 ET | Source: GlobeImmune

El producto candidato contra la hepatitis C de GlobeImmune mejora la respuesta al tratamiento en todos los genotipos IL-28 B, consiguiendo el efecto más pronunciado en los pacientes más difíciles de tratar

LOUISVILLE, CO--(Marketwire - April 19, 2010) - GlobeImmune Inc. anunció hoy los datos finales de la fase 2b del GI-5005, el producto candidato Tarmogen(R) que la empresa está investigando...
April 19, 2010 07:00 ET | Source: GlobeImmune

Le produit de GlobeImmune choisi pour traiter lHépatite C améliore les résultats de fin de traitement pour tous les Génotypes I L-28B, et ceci même chez les patients les plus difficiles à traiter

LOUISVILLE, CO--(Marketwire - April 19, 2010) - GlobeImmune Inc. a annoncé le recueil des données de la Phase 2b concernant le GI-5005, le produit Tarmogen(R), qui est un produit...
April 19, 2010 07:00 ET | Source: GlobeImmune

GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, With the Greatest Effect in the Hardest-to-Treat Patients

LOUISVILLE, CO--(Marketwire - April 19, 2010) - GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company's investigational Tarmogen® product for hepatitis C virus (HCV) infection,...
April 15, 2010 13:00 ET | Source: GlobeImmune

HCV-Arzneimittelkandidat GI-5005 von GlobeImmune verbessert anhaltendes virologisches Ansprechen (SVR) um 10 Prozent und hat damit das Potenzial zum ersten therapeutischen Impfstoff gegen HCV zu werden

LOUISVILLE, COLORADO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. gab heute endgültige Ergebnisse einer Phase-2b-Studie zu GI-5005, dem in Entwicklung befindlichen...
April 15, 2010 13:00 ET | Source: GlobeImmune

El producto candidato GI-5005 contra el VHC de GlobeImmune mejora la respuesta virológica sostenida contra del 10 por ciento, demostrando su potencial para convertirse en la primera vacuna terapéutica contra el VHC

LOUISVILLE, CO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. anunció hoy los datos finales de la fase 2b de GI-5005, el producto candidato Tarmogen(R) bajo investigación de la...
April 15, 2010 13:00 ET | Source: GlobeImmune

GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV

LOUISVILLE, CO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company's investigational Tarmogen® product candidate, demonstrating...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right